Margareta Reis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5286980/publications.pdf

Version: 2024-02-01

304368 414034 1,413 33 22 32 citations h-index g-index papers 34 34 34 1444 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Maternal Use of Antipsychotics in Early Pregnancy and Delivery Outcome. Journal of Clinical Psychopharmacology, 2008, 28, 279-288.	0.7	181
2	The Use of Central Nervous System Active Drugs During Pregnancy. Pharmaceuticals, 2013, 6, 1221-1286.	1.7	128
3	Serum Concentrations of Antidepressant Drugs in a Naturalistic Setting: Compilation Based on a Large Therapeutic Drug Monitoring Database. Therapeutic Drug Monitoring, 2009, 31, 42-56.	1.0	121
4	Therapeutic Drug Monitoring Data on Olanzapine and Its N-Demethyl Metabolite in the Naturalistic Clinical Setting. Therapeutic Drug Monitoring, 2002, 24, 518-526.	1.0	102
5	Therapeutic Drug Monitoring of Racemic Venlafaxine and Its Main Metabolites in an Everyday Clinical Setting. Therapeutic Drug Monitoring, 2002, 24, 545-553.	1.0	62
6	Therapeutic Drug Monitoring of Sertraline: Variability Factors as Displayed in a Clinical Setting. Therapeutic Drug Monitoring, 2000, 22, 446-454.	1.0	61
7	Therapeutic Drug Monitoring of Racemic Citalopram: A 5-Year Experience in Sweden, 1992–1997. Therapeutic Drug Monitoring, 2003, 25, 183-191.	1.0	58
8	Serum Concentrations of Fluoxetine in the Clinical Treatment Setting. Therapeutic Drug Monitoring, 2001, 23, 139-147.	1.0	57
9	Steady-State Concentrations of Mirtazapine, N-Desmethylmirtazapine, 8-Hydroxymirtazapine and their Enantiomers in Relation to Cytochrome P450 2D6 Genotype, AgeÂand Smoking Behaviour. Clinical Pharmacokinetics, 2009, 48, 63-70.	1.6	46
10	Do You Believe It? Verbal Suggestions Influence the Clinical and Neural Effects of Escitalopram in Social Anxiety Disorder: A Randomized Trial. EBioMedicine, 2017, 24, 179-188.	2.7	44
11	Enantioselective Analysis of Citalopram and Metabolites in Adolescents. Therapeutic Drug Monitoring, 2001, 23, 658-664.	1.0	43
12	Therapeutic Drug Monitoring of Escitalopram in an Outpatient Setting. Therapeutic Drug Monitoring, 2007, 29, 758-766.	1.0	40
13	Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Human Psychopharmacology, 2004, 19, 283-291.	0.7	38
14	Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects. A register study. BMJ Open, 2013, e002166.	0.8	37
15	Sedative and hypnotic drugsâ€"Fatal and non-fatal reference blood concentrations. Forensic Science International, 2014, 236, 138-145.	1.3	37
16	Neonatal Complications After Maternal Concomitant Use of SSRI and Other Central Nervous System Active Drugs During the Second or Third Trimester of Pregnancy. Journal of Clinical Psychopharmacology, 2012, 32, 608-614.	0.7	36
17	A Compilation of Serum Concentrations of 12 Antipsychotic Drugs in a Therapeutic Drug Monitoring Setting. Therapeutic Drug Monitoring, 2019, 41, 348-356.	1.0	36
18	Use of tramadol in early pregnancy and congenital malformation risk. Reproductive Toxicology, 2015, 58, 246-251.	1.3	35

#	Article	IF	Citations
19	Ongoing Pharmacological Management of Chronic Pain in Pregnancy. Drugs, 2016, 76, 915-924.	4.9	33
20	Combining escitalopram and cognitive–behavioural therapy for social anxiety disorder: Randomised controlled fMRI trial. British Journal of Psychiatry, 2016, 209, 229-235.	1.7	32
21	Inter- and Intraindividual Pharmacokinetic Variations of Mirtazapine and Its N-Demethyl Metabolite in Patients Treated for Major Depressive Disorder. Therapeutic Drug Monitoring, 2005, 27, 469-477.	1.0	24
22	Serum Levels of Citalopram and Its Main Metabolites in Adolescent Patients Treated in a Naturalistic Clinical Setting. Journal of Clinical Psychopharmacology, 2002, 22, 406-413.	0.7	23
23	Antipsychotics â¿¿ Postmortem fatal and non-fatal reference concentrations. Forensic Science International, 2016, 266, 91-101.	1.3	22
24	Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial. Translational Psychiatry, 2021, 11, 559.	2.4	21
25	Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations. Journal of Affective Disorders, 2004, 82, 443-6.	2.0	19
26	Recognition of personality disorder and anxiety disorder comorbidity in patients treated for depression in secondary psychiatric care. PLoS ONE, 2020, 15, e0227364.	1.1	19
27	Impact of generic substitution on levetiracetam serum concentration—A prospective study in an outpatient setting. Epilepsy Research, 2017, 134, 54-61.	0.8	16
28	Therapeutic Drug Monitoring of Ziprasidone in a Clinical Treatment Setting. Therapeutic Drug Monitoring, 2008, 30, 682-688.	1.0	15
29	The understanding of core pharmacological concepts among health care students in their final semester. BMC Medical Education, 2015, 15, 235.	1.0	12
30	Drug use in pregnant womenâ€"a pilot study of the coherence between reported use of drugs and presence of drugs in plasma. European Journal of Clinical Pharmacology, 2018, 74, 535-539.	0.8	6
31	A Relative Bioavailability Study of Two Misoprostol Formulations Following a Single Oral or Sublingual Administration. Frontiers in Pharmacology, 2020, 11, 50.	1.6	4
32	On the pedagogy of pharmacological communication: a study of final semester health science students. BMC Medical Education, 2015, 15, 186.	1.0	3
33	Pharmacological treatment of mental health problems in pregnancy and lactation. , 0, , 122-136.		2